-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Future outlook of nonpharmacological treatments for insomnia in adults: clinical trial progress
Richard R Bootzin,Rachel Manber
Editorial: Clinical Investigation
-
Future outlook of nonpharmacological treatments for insomnia in adults: clinical trial progress
Richard R Bootzin,Rachel Manber
Editorial: Clinical Investigation
-
Future outlook of nonpharmacological treatments for insomnia in adults: clinical trial progress
Richard R Bootzin,Rachel Manber
Editorial: Clinical Investigation
-
Future outlook of nonpharmacological treatments for insomnia in adults: clinical trial progress
Richard R Bootzin,Rachel Manber
Editorial: Clinical Investigation
-
Future outlook of nonpharmacological treatments for insomnia in adults: clinical trial progress
Richard R Bootzin,Rachel Manber
Editorial: Clinical Investigation
-
Future outlook of nonpharmacological treatments for insomnia in adults: clinical trial progress
Richard R Bootzin,Rachel Manber
Editorial: Clinical Investigation
-
Future outlook of nonpharmacological treatments for insomnia in adults: clinical trial progress
Richard R Bootzin,Rachel Manber
Editorial: Clinical Investigation
-
Future outlook of nonpharmacological treatments for insomnia in adults: clinical trial progress
Richard R Bootzin,Rachel Manber
Editorial: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation